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Disease free survival (DFS) is a surrogate for Overall Survival (OS) in Localized Prostate Cancer (CaP). 
INTERMEDIATE CLINICAL ENDPOINTS IN CANCER OF THE PROSTATE (ICECaP) Working Group 
Background 
• The most promising approach for decreasing the death rate from prostate cancer is 
by preventing relapse after localized therapy when the disease is of very low 
burden and most vulnerable to therapy (e.g. build upon the benefits of ADT plus 
radiation over radiation alone)  
• The conduct of adjuvant CaP clinical trials is hampered by taking longer than a 
decade to reach the meaningful endpoint of OS.  
• An intermediate clinical endpoint (ICE) that is a robust surrogate for OS could 
accelerate conduct of adjuvant trials 
• There are potential challenges in identifying an ICE for CaP 
• heterogeneous disease with a variable natural history after disease relapse 
• heterogeneous treatments in the localized disease setting 
• impact of comorbidities and non-prostate cancer deaths in older population 
• ICECaP is an international collaboration to determine whether an ICE for OS can 
be identified when assessing the efficacy of localized CaP therapy. 
Objectives 
• Determine whether disease free survival (DFS) is a surrogate for OS for localized 
prostate cancer  
• Determine whether time to disease recurrence (TDR) is a surrogate for disease 
specific survival (DSS) for localized prostate cancer 
Study Design 
• Meta analysis of pooled data from early stage CaP randomized trials.  
• Systematic reviews of studies are performed following the PRISMA statement 
(http://www.prisma-statement.org).  
• Trial Eligibility: 
Randomized, controlled trials for localized CaP 
Conducted in Canada, UK, Europe, Australia/New Zealand, US 
Studies with accrual completed /terminated  
Exclude trials that have a primary endpoint such as safety, toxicity, QOL, feasibility, 
dosimetry, patient decision making without systematic long-term follow-up 
• Buyse’s two-stage validation model (Buyse et al, 2000, 2011) 
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 *other causes: n=5082 (64%); unknown cause: n=645 (8%); **if metastasis occurs prior to local/regional 
recurrence or within 3 months of a local/recurrence event; ***Recurrence site cannot be determined for 4 
studies (EPC24, EPC25, ECOG3886, Australian Study Yeoh et al). 
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Conclusions and Future Work 
•DFS can be used as a surrogate of OS and TDR as a surrogate 
of DSS in both RT and RP based studies. 
•The trend is consistent when RT based trials are analyzed 
separately.  
• Future work: 
 Determine surrogacy threshold effect  
 Assess surrogacy of Metastasis Free Survival  
 Pharmaco-economic analyses of using surrogate and 
preventing relapses 
Condition 1: Surrogate and final endpoints must be correlated 
  N % 
Type of treatment 
201 1 Comparing primary therapies  
RP+/-Adj RT or ADT  5518 26 
RT dose  1366 6 
RT+/-ADT  11619 55 
No primary therapy +/- ADT/other  2436 12 
Age at randomization 
14 0 NA  
64 or younger 6043 29 
65-74  11857 56 
75 or older  3226 15 
D'Amico risk group 
1618 8 NA  
Low  2096 10 
INTM  4453 21 
High  12973 61 
Type of First Failure Event 
Disease recurrence PC death 
Non-PC 
death 
/unknown 
No. (%) of 
Events 
Local/ 
Regional  
Distant 
Metastasis**  
Unknown 
sites*** 
Total 
OS 7996(37.8) 2269(28) 5727(72)* 
DSS 2269(10.7) 2269(100) 
DFS 9509(45.0) 1560 1511 1233 4304(45) 381(4) 4824(51) 
TDR 4685(22.2) 1560 1511 1233 4304(92) 381(8) 
Condition 2: Treatment effects on both endpoints must be correlated* 
OS at 8 yrs versus DFS at 5 yrs  DSS at 8 yrs versus TDR at 5 yrs 
No. of unit R-square (95% CI) No. of unit R-square (95% CI) 
All 56* 0.86 (0.78,0.90) 56* 0.80 (0.70,0.85) 
RT-based 37 0.68 (0.48,0.78) 37 0.71 (0.52,0.80) 
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 Type of first failure event for DFS by Study 
Between DFS and OS Between TDR and DSS 
 
  No. of units 
(patients) 
Kendall’s Tau 
(95%CI) 
No. of units 
(patients) 
Kendall’s Tau 
(95%CI) 
All patients 31(21,140) 0.85(0.85,0.86) 28(20,496)* 0.68(0.67,0.69) 
 RT based 21(13,186) 0.84(0.83,0.84) 19(12,770) 0.66(0.65,0.67) 
 Correlation at the patient level estimated from Plackett’s copula   
 *excluding 3 studies with number of PC- death <3 
*The analysis unit comprised of 24 trials with 31 units and when arm specific units are used 
excluding 3 studies with median follow-up < 6 years, we have 56 units (31units x 2 arms - 6arms 
from 3 trials=56 units) 
R-square from weighted linear regression of Kaplan Meier estimates of endpoints 
R-square from weighted linear regression of treatment effects (log-HR) on endpoints 
Log(HR)-OS versus Log(HR)-DFS Log(HR)-DSS versus Log(HR)-TDR 
No. of units R-square (95% CI)** No. of units R-square (95% CI)** 
All 31 0.73 (0.53,0.82) 28* 0.63 (0.36,0.75) 
RT-based 21 0.75 (0.48,0.84) 19 0.63 (0.27,0.77) 
*excluding 3 studies with number of PC- death <3 
• Not Suitable (36 trials) 
• Still in Discussion (8 trials) 
• Future participate*(12 trials) 
Letters sent 
99 trials 
Agreed to participate 
(43 trials: 28,905 pts) 
102 trials Identified* 
(completed or ongoing) 
28 trials with IPD on 
22,825 in repository 
24 trials with 21,140 pt data 
suitable for DFS analysis 
*Pending publication/data maturity 
*as of June 2013 
*No. of units for analyses = 31 
as 5 trials were split to multiple 
units by type of primary 
therapy or if there were 
multiple experimental arms.  
 *Hazard ratios were estimated from Cox proportional hazards models 
